Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06669013 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas

Study acronym: FollowTheDIN
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated November 1, 2024 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
Data from 40 patients are planned to be included in the study to randomize approximately 10 patients. This study involves patients with advanced/metastatic GD2-positive rhabdomyosarcoma after progression on 1st line of chemotherapy, advanced/metastatic GD2-positive Ewing sarcoma after progression on 1st line of chemotherapy and advanced/metastatic GD2-positive osteosarcoma after progression on 1st line of chemotherapy. All patients will receive therapy until disease progression (a total of 6 courses of immunotherapy). The primary objective of the study is to determine the efficacy and safety of dinutuximab beta with investigator's choice of chemotherapy.
Trial Details
NCT Number NCT06669013
Lead Sponsor N.N. Petrov National Medical Research Center of Oncology
Conditions
(from sponsor)		 Bone Sarcoma, Embryonal Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma
Related terms Bone Neoplasms, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov